Topics: The rally since March 23; Recent antibody tests in Europe show large numbers of unreported infections, which could signal an earlier onset of herd immunity than you might think.

On March 20th and again on March 30th, I wrote that equity markets at prevailing lower levels were pricing in a lot of bad news (an entire decade for earnings to regain their prior peak vs historical average of usually less than three years). I also included a blizzard of charts showing the long history of markets rallying well in advance of GDP, employment and an end to bank failures, corporate defaults and consumer delinquencies. When you combine all of that with what took place around March 23 (Fed bazooka announcements, large short positions in US equity markets and a decline in the second derivative of COVID-19 infections in hotspots like Italy and NYC), you have a recipe for a sharp and sudden market rise. Now, after the rally, equity markets are pricing in a lot of good news given what still lies ahead, with P/E multiples already back at 16x 2021 consensus earnings (from a low of 13x), and even higher if you assume as I do that 2021 earnings projections will come down. Equity advances probably get slower and less one-directional from here; the fastest gains generally occur when everyone thinks the only path is down.

March 23rd Fed bazooka announcements:
- Primary Market Corporate Credit Facility (PMCCF) for new bond and loan issuance.
- Secondary Market Corporate Credit Facility (SMCCF) to provide liquidity for outstanding corporate bonds.
- Term Asset-Backed Securities Loan Facility (TALF), to support student loans, auto loans, credit card loans, loans guaranteed by the Small Business Administration (SBA), and certain other assets.
- Expand the Money Market Mutual Fund Liquidity Facility (MMLF) to include a wider range of securities, including municipal variable rate demand notes (VRDNs) and bank certificates of deposit.
- Expand the Commercial Paper Funding Facility (CPFF) to include high-quality, tax-exempt commercial paper.
After the first wave: getting back to “normal”, and the importance of virus/antibody testing

How will countries try and get back to normal after the first COVID infection wave has subsided? This is an issue that several countries in Asia are already facing (although there has been a recent and worrisome spike in Singapore), and which countries like Austria and Norway may be facing soon.

At the risk of over-simplification, there are three main approaches a country could take after the first COVID-19 wave subsides (and in each case, restrictions on international travel will be required to prevent importation of new cases):

- **Keep flattening the curve and gradually let people go back to work as infection levels drop.** The problem with this approach: it only takes a small number of infectious people wandering around to ignite a second infection wave without a healthcare system that can track down and isolate new clusters. It is still unclear if seasonal changes (sunlight/heat/humidity) will materially change the virus dynamics, and even if they did, a new wave could appear in the fall.

- **Relax lockdowns, and use a swat-team approach to identify any new clusters.** Immediately isolate and quarantine new clusters as well as their contacts via contact tracing. Life gets back to normal faster, but this approach works best when combined with an extremely well-organized healthcare system, a compliant population that obeys social distancing rules, a legal system that allows the government to use a wide variety of tracking approaches (credit card receipts, cell phones, close circuit television, GPS, etc) to monitor the population and enforce rules; and when the run rate of new daily infections is low enough to handle the influx of new cases. I consider this scenario to be the most likely in many countries.

- **Through serological testing, identify people who have been exposed to the disease, possess the antibodies to prevent them from infecting others or getting sick again, and let them get back to work.** Biggest challenge: requires herd immunity for maximum impact, which we discuss on the next 2 pages.

---

1 Best illustrated via a [visualization](#) from Grant Sanderson at 3 Blue 1 Brown

2 This approach can be thought of as a real-life version of “**Code 2319**” in the movie *Monsters Inc*, when a swat team descends on anyone infected by a human article of clothing, and then quarantines and decontaminates them.
The latest antibody test results in Europe, and what they might indicate for herd immunity

Over the last 3-4 days, a small number of research institutions and hospital systems in Europe have released the results of random serological tests for COVID-19 antibodies. There are only a few so far:

- Denmark\(^3\), where 2.7% of 1,500 people tested antibody-positive 34 days after its outbreak
- Heinsberg, Germany where 14% of 509 people tested antibody-positive 73 days after its outbreak
- Scotland, where 1.2% of 500 people tested antibody-positive 21 days after its outbreak

These results indicate much higher levels of COVID-19 exposure than by simply looking at reported case to population ratios for each region (chart below, left), which are at least one order of magnitude smaller. In simpler terms, serology results indicate that there’s a large number of unreported infections due to people who couldn’t get tested, only had mild symptoms, were asymptomatic, etc. And since antibodies show up with a lag, current infection levels are likely to be even higher than serology results indicate.

Now let’s get to the next and even more important question: how long until herd immunity might arrive simply through passage of time? Antibody presence of 2.7% and 14% might seem small, and it would be if viruses evolved linearly. But viruses only attack susceptible hosts, and as they progress, the susceptible population shrinks. An epidemiologist contact at the University of Toronto was pleased to see the Denmark and Heinsberg results, and suggested we look at them through the lens of our “SIR” model\(^4\) to see why, using serology results as a better measure of “true” infection rates. Here’s what we found: herd immunity, estimated as 60% population exposure\(^5\), might be closer than you think. Following each serological observation along the red curve to the dotted line in the 2\(^{nd}\) chart, much greater levels of immunity could be one month away in Heinsberg, and two months away in Denmark.

---

\(^3\) The best studies, like the Danish one, will conduct “ELISA” tests and then cross check them with a more specific test called a viral neutralization assay to make sure the tests are right.

\(^4\) “SIR” models are used to track the distribution of a population exposed to a virus over time into three categories: “susceptible”, “infected” and “removed” (recovered or deceased). The susceptible population declines rapidly once the pool of potential hosts migrates into the removed category. However, the susceptible population does not decline to zero since immune individuals act as “fire-breaks” who buffer susceptible individuals from infection.

\(^5\) Herd immunity requires at least 60% exposure since the effective reproductive number must fall below 1.0x. Assuming an initial reproductive number of 2.5, that would require a 60% decline in the susceptible population.
To be clear, there are a lot of uncertainties: these models are highly sensitive to input parameters (particularly the timing of outbreak and serology test results); serology tests for COVID-19 may involve false positives (unclear how large an issue this might be), as well as people who test positive with “insufficient” antibodies; sample populations might not be representative of the whole; and they may not be applicable across countries. Furthermore, even if herd immunity were reached, the virus would still spread, but at a more manageable rate involving smaller clusters that are dealt with independently.

Even with all these caveats, the projections on the prior page are helpful in illustrating the evolution of the virus and its antibody aftermath, and provide a rationale for serological testing as part of a “back to work” plan in the summer or fall (under the presumption that a society can organize itself to do it). We will update the chart above as new serological observations emerge.

Serology tests: who’s using them, who’s making them and what the CDC has to say about it

The CDC and private companies are scrambling to produce serology tests; the UK has ordered 3.5 million, Germany may use them to issue immunity certificates to survivors, and China and Singapore are using them to measure more accurate infection rates. On top of that, the US FDA is allowing doctors to use serology tests to identify recovered patients whose antibodies could treat emergency cases of the disease. There are now over 50 companies that have informed the FDA of their intention to sell serology testing kits in the US, many of which are already available. However, to be clear, these kits are self-validated, and the FDA requires that the following disclosures be included:

- The tests have not been reviewed by the FDA
- Negative results do not rule out SARS-CoV-2 infection. Follow-up testing with a molecular diagnostic should be considered to rule out infection
- Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status
- Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains

These are strongly worded caveats, which some counties already appear prepared to disregard, or at least acknowledge as “acceptable” risk as the world focuses on getting back to work.

Sources:
“Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications”, Fan Wu et al, Shanghai Public Health Clinical Center, Fudan University, March 30, 2020
“Preliminary results and conclusions of the COVID-19 case cluster study”, Bonn University Hospital, March 2020
“Serological analysis of 1000 Scottish blood donor samples for anti-SARS-COV-2 antibodies collected in March 2020”, Oxford Immunology Consortium, Scottish National Blood Transfusion Service and University of Kent
“Blood banks will test whether donors have had coronavirus”, SN.DK, April 4, 2020

---

6 A recent paper from Fudan University reported that one third of recovered patients in a 175-person cohort did not possess high levels of COVID-19 antibodies normally associated with disease recovery. They concluded that the low-antibody patients might have recovered since their T-cells, cytokines or other parts of their immune systems defeated the virus instead. Whether low-antibody patients are still susceptible to the disease remains to be determined.
Purpose of This Material: This material is for information purposes only. The views, opinions, estimates and strategies expressed herein constitutes Michael Cembalest’s judgment based on current market conditions and are subject to change without notice, and may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such.

GENERAL RISKS & CONSIDERATIONS
Any views expressed herein or products discussed in this material may not be appropriate for all individuals and are subject to risks. Investors may get back less than they invested, and past performance is not a reliable indicator of future results. Asset allocation / diversification does not guarantee a profit or protect against loss. Nothing in this material should be relied upon in isolation for the purpose of making an investment decision. You are urged to consider carefully whether the services, products, asset classes (e.g. equities, fixed income, alternative investments, commodities, etc.) or strategies discussed are suitable to your needs. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. For this and more complete information, including discussion of your goals/situation, contact your J.P. Morgan representative.

NON-RELIANCE
Certain information contained in this material is believed to be reliable; however, JPM does not represent or warrant its accuracy, reliability or completeness, or accept any liability for any loss or damage (whether direct or indirect) arising out of the use of all or any part of this material. No representation or warranty should be made with regard to any computations, graphs, tables, diagrams or commentary in this material, which are provided for illustration/reference purposes only. The views, opinions, estimates and strategies expressed in this material constitute our judgment based on current market conditions and are subject to change without notice. JPM assumes no duty to update any information in this material in the event that such information changes. Views, opinions, estimates and strategies expressed herein may differ from those expressed by other areas of JPM, views expressed for other purposes or in other contexts, and this material should not be regarded as a research report. Any projected results and risks are based solely on hypothetical examples cited, and actual results and risks will vary depending on specific circumstances. Forward-looking statements should not be considered as guarantees or predictions of future events.

Nothing in this document shall be construed as giving rise to any duty of care owed to, or advisory relationship with, you or any third party. Nothing in this document shall be regarded as an offer, solicitation, recommendation or advice (whether financial, accounting, legal, tax or other) given by J.P. Morgan and/or its officers or employees, irrespective of whether or not such communication was given at your request.

J.P. Morgan and its affiliates and employees do not provide tax, legal or accounting advice. You should consult your own tax, legal and accounting advisors before engaging in any financial transactions.

LEGAL ENTITY, BRAND & REGULATORY INFORMATION
In the United States, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A. and its affiliates (collectively “JPMCB”) offer investment products, which may include bank-managed investment accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC (“JPM”), a member of FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPM and CIA are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

In Luxembourg, this material is issued by J.P. Morgan Bank Luxembourg S.A. (“JPMBL”), with registered office at European Bank and Business Centre, 6 route de Treves, L-2633, Senningerberg, Luxembourg. R.C.S Luxembourg B10.958. Authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A. is authorized as a credit institution in accordance with the Law of 5th April 1993. In the United Kingdom, this material is issued by J.P. Morgan Bank Luxembourg S.A.—London Branch. Prior to Brexit (Brexit meaning that the UK leaves the European Union under Article 50 of the Treaty on European Union, or, if later, loses its ability to passport financial services between the UK and the remainder of the EEA), J.P. Morgan Bank Luxembourg S.A.—London Branch is subject to limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority. Details about the extent of our regulation by the Financial Conduct Authority and the Prudential Regulation Authority are available from us on request. In the event of Brexit, in the UK, J.P. Morgan Bank Luxembourg S.A.—London Branch is authorised by the Prudential Regulation Authority, subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. In Spain, this material is distributed by J.P. Morgan Bank Luxembourg S.A., and its affiliates and employees do not provide tax, legal or accounting advice. You should consult your own tax, legal and accounting advisors before engaging in any financial transactions.

In Germany, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Frankfurt Branch, registered office at Taunusstor 1 (TaunusTurm), 60310 Frankfurt, Germany, jointly supervised by the Commission de Surveillance du Secteur Financier (CSSF) and the European Central Bank (ECB), and in certain areas also supervised by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). In Italy, this material is distributed by J.P. Morgan Bank Luxembourg S.A.—Milan Branch, registered office at Via Catena Adalberto 4, Milan 20121, Italy and regulated by Bank of Italy and the Commissione Nazionale per le Società e la Borsa (CONSOB). In the Netherlands, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch, with registered office at World Trade Centre, Tower B, Strawinskylaan 1135, 1077 XX, Amsterdam, The Netherlands. J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is also authorised by the Commission de Surveillance de l’Union Européenne (AMFER) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan Bank Luxembourg S.A. under registration number 71651845. In Denmark, J.P. Morgan Bank Luxembourg S.A. is authorised and regulated by the Danish Financial Services Authority (DFSA). J.P. Morgan Bank Luxembourg S.A. is authorised and regulated by the Danish Financial Services Authority (DFSA) and the Danish Financial Supervisory Authority (DFSA). J.P. Morgan Bank Luxembourg S.A. is also subject to the supervision of Finanstilsynet (Danish FSA) and registered with Finanstilsynet as a branch of J.P. Morgan Bank Luxembourg S.A. under code 15322. In Sweden, this material is distributed by J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial, with registered office at Hamngatan 15, Stockholm, 11147, Sweden. J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A., Stockholm Branch is also subject to the supervision of Finansinspektionen (Swedish FSA). Registered with Finansinspektionen as a branch of J.P. Morgan Bank Luxembourg S.A. In France, this material is distributed by JPMorgan Chase Bank, N.A. (“JPMCB”), Paris branch, which is regulated by the French banking authorities Autorité de Contrôle Prudentiel et de Résolution.
and Autorité des Marchés Financiers. In Switzerland, this material is distributed by J.P. Morgan (Suisse) SA, which is regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA).

In Hong Kong, this material is distributed by JPMCB, Hong Kong branch. JPMCB, Hong Kong branch is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission of Hong Kong. In Hong Kong, we will cease to use your personal data for our marketing purposes without charge if you so request. In Singapore, this material is distributed by JPMCB, Singapore branch. JPMCB, Singapore branch is regulated by the Monetary Authority of Singapore. Dealing and advisory services and discretionary investment management services are provided to you by JPMCB, Hong Kong/Singapore branch (as notified to you). Banking and custody services are provided to you by JPMCB Singapore Branch. The contents of this document have not been reviewed by any regulatory authority in Hong Kong, Singapore or any other jurisdictions. This advertisement has not been reviewed by the Monetary Authority of Singapore. JPMorgan Chase Bank, N.A., a national banking association chartered under the laws of the United States, and as a body corporate, its shareholder’s liability is limited.

JPMorgan Chase Bank, N.A. (JPMCBNA) (ABN 43 074 112 011/AFS Licence No: 238367) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority. Material provided by JPMCBNA in Australia is to “wholesale clients” only. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Corporations Act 2001 (Cth). Please inform us if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

JPMS is a registered foreign company (overseas) (ARBN 109293610) incorporated in Delaware, U.S.A. Under Australian financial services licensing requirements, carrying on a financial services business in Australia requires a financial service provider, such as J.P. Morgan Securities LLC (JPMS), to hold an Australian Financial Services Licence (AFSL), unless an exemption applies. JPMS is exempt from the requirement to hold an AFSL under the Corporations Act 2001 (Cth) (Act) in respect of financial services it provides to you, and is regulated by the SEC, FINRA and CFTC under US laws, which differ from Australian laws under the Corporations Act 2001 (Cth) in respect of financial services it provides to you, and is regulated by the SEC, FINRA and CFTC under US laws, which differ from Australian laws. Material provided by JPMS in Australia is to “wholesale clients” only. The information provided in this material is not intended to be, and must not be, distributed or passed on, directly or indirectly, to any other class of persons in Australia. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Act. Please inform us immediately if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

This material has not been prepared specifically for Australian investors. It:

• may contain references to dollar amounts which are not Australian dollars;
• may contain financial information which is not prepared in accordance with Australian law or practices;
• may not address risks associated with investment in foreign currency denominated investments; and
• does not address Australian tax issues.

With respect to countries in Latin America, the distribution of this material may be restricted in certain jurisdictions. We may offer and/or sell to you securities or other financial instruments which may not be registered under, and are not the subject of a public offering under, the securities or other financial regulatory laws of your home country. Such securities or instruments are offered and/or sold to you on a private basis only. Any communication by us to you regarding such securities or instruments, including without limitation the delivery of a prospectus, term sheet or other offering document, is not intended by us as an offer to sell or a solicitation of an offer to buy any securities or instruments in any jurisdiction in which such an offer or a solicitation is unlawful. Furthermore, such securities or instruments may be subject to certain regulatory and/or contractual restrictions on subsequent transfer by you, and you are solely responsible for ascertaining and complying with such restrictions. To the extent this content makes reference to a fund, the Fund may not be publicly offered in any Latin American country, without previous registration of such fund’s securities in compliance with the laws of the corresponding jurisdiction. Public offering of any security, including the shares of the Fund, without previous registration at Brazilian Securities and Exchange Commission-CVM is completely prohibited. Some products or services contained in the materials might not be currently provided by the Brazilian and Mexican platforms.

References to “J.P. Morgan” are to JPM, its subsidiaries and affiliates worldwide. “J.P. Morgan Private Bank” is the brand name for the private banking business conducted by JPM.

This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan representative.

© 2020 JPMorgan Chase & Co. All rights reserved.